ADMA Biologics ADMA 深 沪
等待开盘 09-14 09:30:00 美东时间
9.23
-0.160
-1.70%
华盛通- 最 高9.50
- 今 开9.44
- 成交量 226.68万股
- 最 低 9.195
- 昨 收 9.39
- 总市值 206.74万
- 52周最高 20.458
- 市盈率 静 15.38
- 换手率 1.01%
- 52周最低 7.2101
- 委 比 69.44%
- 总股本 0.00亿
- 历史最高 25.67
- 量 比 1.14
- 振 幅 3.25%
- 历史最低 1.01
- 每 手 1
- 风险率 3.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADMA Biologics Leans on ASCENIV in Earnings Call
ADMA Biologics Inc (($ADMA)) has held its Q2 earnings call. Read on for the mai...
08-21 08:24
ADMA Biologics (ADMA) Receives a Buy from Canaccord Genuity
In a report released today, Gary Nachman from Canaccord Genuity maintained a Bu...
08-06 19:18
财报速睇 | ADMA Biologics 2026财年Q2营收1.24亿美元，同比增长2.0%；归母净利润0.38亿美元，同比增长10.5%
华盛资讯8月6日讯，ADMA Biologics公布2026财年Q2业绩，公司Q2营收1.24亿美元，同比增长2.0%，归母净利润0.38亿美元，同比增长10.5%。
08-06 07:52
财报速睇 | ADMA Biologics 2026财年Q2营收1.24亿美元，同比增长2.0%；归母净利润0.38亿美元，同比增长10.5%
华盛资讯8月6日讯，ADMA Biologics公布2026财年Q2业绩，公司Q2营收1.24亿美元，同比增长2.0%，归母净利润0.38亿美元，同比增长10.5%。
08-06 05:40
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
08-06 04:24
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $124.395 million...
08-06 04:14
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
ADMA Biologics, Inc. (ADMA) will announce its second quarter 2026 financial results on August 5, 2026, followed by a conference call and webcast at 4:30 p.m. ET. Participants must register in advance to receive dial-in details. The event will also be available via live webcast and archived replay on the company’s investor website. ADMA is a biopharmaceutical company focused on manufacturing and developing specialty biologics for treating immunode...
07-29 11:00
Next Century Growth Investors exits Bloom Energy, Coherent; adds DigitalOcean in Q2
In its Q2 portfolio update, Next Century Growth Investors disclosed nine new positions across three sectors. The industrial additions were Park Aerospace Corp. (PKE), IPG Photonics Corporation (IPGP),...
07-24 23:00
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.
07-16 02:20
